beta -ALKOXYACRYLATES AGAINST MALARIA

Abstract: The invention relates to the use of beta -alkoxyacrylates of formulae (IA) or (IB) wherein R, R<1>, R<6>, R<7>, R<8>, X and Z are as defined herein, as therapeutically active substances, especially in the treatment or prophylaxis of malaria and to medicaments containing these substances.

Description: β-Alkoxyacrylates against malaria The invention relates to compounds of the general formulae wherein R 1 is lower alkyl X is N or CH A 1 R in IA is ^ ^ Ial wherein Y is S or O and A 1 is phenyl, which may be substituted by one or more substituents, selected from halogen, lower alkoxy, lower alkyl, CF3 ) NO2, NH2, phenoxy or CF3- phenoxy; naphthyl; isothiazol-3-yl; thiazol-2-yl, optionally substituted by lower alkoxy alkoxy alkyl, lower alkyl, lower alkoxycarbonyl or lower acetoxyalkyl; thiadiazol-2-yl, optionally substituted by lower alkylthio, lower alkinylthio, cycloalkyl- alkylthio, CF3 or -NHC6H4CF3; quinoxalin-2-yl, optionally substituted by halogen or lower alkyl; benzoxazol-2-yl; benzotriazine, optionally substituted by an oxo-group; and quinolin-2-yl; wherein R 2 is hydrogen, lower alkoxycarbonyl, CF3, lower alkyl, cycloalkyl, lower alkoxyalkyl, lower alky lthio alkyl or lower alkoxy and A 2 is phenyl, which may be substituted by one or more substituents, selected from lower alkyl, CF3, halogen, lower alkylthio, lower alkoxy or NO 2; -C(O)C 6 H 5 ; -C(CH 3 )=CH-C 6 H 4 -lower alkyl; -CH=CH-C6H5; pyridin-2-yl; pyridin-3-yl; pyridin- 4-yl; thiazol-5-yl, optionally substituted by lower alkyl; thien-3-yl, optionally substituted by lower alkyl; thien-2-yl, optionally substituted by halogen; quinolin-2-yl; naphthyl, benzo[b]thiophen-2-yl, optionally substituted by lower alkyl or halogen; or benzo[b]furan-2-yl; R 3 ✓ A 3 or ^^ ' W Ia3 wherein W is S, O, NH or CH 2 ; R 3 is hydrogen or lower alkyl and A 3 is 5-acetoxy-6-acetoxymethyl-5,6-dihydro-2H- pyran or phenyl, which may be substituted by one or more substituents, selected from halogen, CF3 or lower alkyl; or ^ Ia4 wherein A 4 is phenyl, which may be substituted by one or more substituents, selected from NO2, lower alkoxy, halogen, CF3,phenyloxy, styryl-phenyl or (2-CF3- or Cl-phenyl)-furan-2-yl; benzo[l,3]dioxol- 5-yl, optionally substituted by halogen; isoxazol-4- yl, optionally substituted by phenyl or lower alkoxyalkoxy; quinolin-3-yl; pyridin-2-yl; pyridin- 3-yl, pyridin-4-yl; furyl; thien-2-yl; thien-3-yl; -C≡C-C(CH 3 ) 3 ; -C≡C-C 6 H 5 ; indolizin-2-yl, optionally substituted by lower alkyl; benzofuran- 2-yl; benzopyran-3-yl or dihydrobenzo[b]thiophen- 5-yl; wherein R 4 is hydrogen or lower alkyl; and A 5 is phenyl, which may be substituted by one or more substituents, selected from lower alkyl, lower alkoxy, NO2, halogen, cyano or CF3; pyridin-2-yl; pyridin-4-yl; quinolin-2-yl; quinolin-3-yl; naphthyl; pyrrol-2-yl, optionally substituted by lower alkyl; furan-2-yl, furan-3-yl; thien-2-yl; thien-3-yl, optionally substituted by halogen and lower alkyl; thiazol-2-yl, optionally substituted by C6H4CI; thiazol-4-yl, optionally substituted by phenyl; benzo[b]thiophen-2-yl, optionally substituted by halogen; or benzo[b]thiophen-3-yl; or ^ ^ /' Ia6 wherein A 6 is phenyl, optionally substituted by CF3; or ^ ^^ A? Ia7 wherein A 7 is phenyl, optionally substituted by CF3; or -(CH 2 ) n -A8 Ia8 wherein n is 4 and A 8 is phenyl, which may be substituted by one or more substituents, selected from CF3, halogen or -CH=N-OCH 2 -CO-OCH 3 ; naphthyl or pyridin-4-yl; wherein A 9 is phenyl, optionally substituted by CF3; and wherein in formula IB R 6 -R 8 are hydrogen, lower alkyl or lower alkoxy and is hydrogen; lower alkoxy; lower alkyl; or halogen or V Ibl wherein V is O, -N(CH 3 )-, -S- and B 1 is phenyl, optionally substituted by halogen or alkyl; quinolin-8-yl; pyrimidin-2-yl; -CH(CfΪ 3 )- C 6 H 5 ; or -CH 2 -C 6 H 5 ; wherein m is 0 or 1; and B 2 is phenyl, optionally substituted by halogen, lower alkyl or CF 3 ; or benzo[b]thiophen-5-yl; O or • o- ^ ^ B 3 ib3 wherein B 3 is phenyl, optionally substituted by CF 3 ; wherein R 5 is hydrogen, lower alkyl or lower alkoxyalkyl and B 4 is phenyl, optionally substituted by CF 3 ; pyridin- 2-yl; or thiazolin-5-yl, optionally substituted by lower alkyl; or ^^ Ib5 wherein B 5 is phenyl; -C≡C-C(CH 3 ) 3 ; or thien-3-yl; as well as pharmaceutically acceptable salts of compounds of formulae LA and IB. All possible stereoisomers as well as their racemates are included in formulae IA and IB. It has now surprisingly been found that compounds of the present invention are useful against malaria. Every year, between 300 and 500 million people develop malaria. Close to 3 million people die as a result of this disease, most of them children and nearly all of them living in tropical Africa. Fifty years ago, many people thought that malaria could be completely eradicated. But over the past twenty years, malaria has been making a comeback. For years, chloroquine has been the standard treatment, but in some areas the malaria parasite is resistant to chloroquine and to cocktails of almost all the older antimalarials. Around 40% of the world's population now live in areas where malaria is found. The compounds of the invention have the property that they are active not only against chloroquine-sensitive, but also against chloroquine-resistant malaria pathogens. For this reason they are very well suited for the prophylaxis and treatment of malaria, especially in cases where the malaria pathogens are resistant to chloroquine. Most of the above described β-alkoxyacrylates and their salts are known compounds. They are described in the following documents EP 379 098, EP 299 694, WO 9007493, EP 278 595, EP 463 488, EP 370 629, EP 475 158, EP 474 042, EP 178 826, DE 3 519 280, EP 433 233, EP 460 575 and EP 254 426 as compounds with fungicidal activity for use in agriculture. The following compounds of formula IA5 are novel: wherein R 1 is lower alkyl, X is N or CH, R 4 is hydrogen or lower alkyl and A 5 is phenyl, which may unsubstituted or substituted by one or more substituents, selected from lower alkyl, lower alkoxy, NO2, halogen, cyano or CF3; pyridin-2-yl; pyridin-4-yl; quinolin-2-yl; quinolin-3-yl; naphthyl; pyrrol-2-yl, optionally substituted by lower alkyl; furan-2-yl, furan-3-yl; thien-2-yl; thien-3-yl, optionally substituted by halogen and lower alkyl; thiazol-2-yl, optionally substituted by C6H4CI; thiazol-4-yl, optionally substituted by phenyl; benzo[b]thiophen-2-yl, optionally substituted by halogen; or benz o [b] thiophen-3 -yl ; as well as their pharmaceutically acceptable salts. Objects of the present invention are the use of the mentioned compounds of formulae LA and IB and their pharmaceutically acceptable salts thereof against chloroquine-sensitive and chloroquine resistant malaria pathogens, the use of these compounds for manufacture of corresponding medicaments, medicaments, containing these compounds and their salts as well as new compounds of formula IA5 per se. The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination. As used herein, the term "lower alkyl" denotes a straight or branched-chain alkyl group containing from 1-4 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t- butyl and the like. The term "halogen" denotes chlorine, iodine, fluorine or bromine. The term "lower alkoxy" denotes an alkyl group, as defined earlier which is attached via an oxygen atom. The term "cycloalkyl" denotes saturated cyclic hydrocarbon residues containing 3 to 6 carbon atoms. The present invention embraces all possible racemates and their optical antipodes. Preferred compounds of formula LA are especially those of formula IA5, in which R 1 is methyl, X is CH, R 4 is hydrogen and A 5 is phenyl, substituted by one or more substituents, selected from CF 3 , bromine, chlorine, methoxy, NO 2 or lower alkyl; or naphthyl or thienyl. Compounds of formula IA2 in which R 1 is methyl, X is CH, R 2 is hydrogen or lower alkyl and A 2 is phenyl, substituted by CF 3 , chloro, fluoro, methyl, t-butyl or SCH 3 are also preferred. Another group of preferred compounds is the following: in which R 1 is methyl, X is CH, Y is O or S and A 1 is phenyl, optionally substituted by methyl, isopropyl, t-butyl, bromo, chloro, CF 3 or methoxy; naphthalenyl; or thiadiazolyl, optionally substituted by thiomethyl or propynylthiocyclopropyl. The following intermediates which are used in the process for preparation of compounds of formulae IA4 show also a pharmaceutical activity against malaria pathogens: The compounds of formulae IA and IB can be prepared as described in the documents cited above. In addition, compounds of formulas IA1-LA9 and IB1-IB5, can be prepared in accordance with schemes 1-14. Scheme 1 VI V IA1 wherein the substituents have the significances described above. Scheme 2 IA2 wherein the substituents have the signifcances described above. Scheme 3 wherein the substituents have the significances described above. Scheme 4 XIII IA4 wherein the substituents have the significances described above. XIV IA5 wherein the substituents have the significances described above. Scheme 6 A b CHO -Br A 6 Br XV XVI XVII IA6 wherein the substituents have the significances described above. Scheme 7 A' wherein the substituents have the significances described above. Scheme 8 wherein the substituents have the significances described above. wherein the substituents have the significances described above. Scheme 10 wherein the substituents have the significances described above. Scheme 11 wherein the substituents have the significances described above. Scheme 12 IB3 wherein the substituents have the significances described above. IB4 wherein the substituents have the significances described above. Scheme 14 XXVII IB5 wherein the substituents have the significances described above. The novel compounds of formula IA5 can be prepared in accordance with scheme 5 and by Examples 164-206. As mentioned earlier, the β-alkoxyacrylates of general formulae LA and IB in accordance with the invention and their pharmaceutically usable salts have valuable pharmaceutical properties. In particular, they have a very good activity against malaria pathogens. Their activity is equally good against chloroquine-resistant strains of the pathogen as against chloroquine-sensitive strains. Accordingly, the present compounds can also be used for the prophylaxis and cure of malaria even in those cases where the pathogen does not respond to chloroquine. In the following table are described the tested compounds: Preferred compounds are also those of formula LAI wherein R 1 is methyl, X is CH, Y is S or O, A 1 is phenyl, which may be substituted by one or more substituents, selected from hal, lower alkoxy, lower alkyl, CF3, NO2, NH2, phenoxy, or CF3-phenoxy. Such compounds can be prepared according to the procedure set in example 1 of EP 278595, like the following specific compounds: (E)-2-[2-(2-Bromo-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester; (E)-3-methoxy-2-[2-(4-phenoxy-phenoxymethyl)-phenyl]-acrylic acid methyl ester; (E)-3-methoxy-2-[2-[4-(4-triπuoromethyl-phenoxy)-phenoxy- methyl]-phenyl]-acrylic acid methyl ester; (E)-3-methoxy-2-[2-(4-methoxy-2-nitro-phenoxymethyl)-phenyl]- acrylic acid methyl ester; (E)-2-[2-(2,4-dibromo-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester; (E)-2-[2-(2-chloro-4-methyl-phenoxymethyl)-phenyl]-3-methoxy- acrylic acid methyl ester; (E)-2-[2-(2-chloro-4-trifluoromethyl-phenox3onethyl)-phenyl]-3- methoxy-acrylic acid methyl ester; (E)-3-methoxy-2-(2-pentafluorophenyloxymethyl-phenyl)-acrylic acid methyl ester; (E)-2-[2-(2,4-dichloro-phenylsulfanylmethyl)-phenyl]-3-methoxy- acrylic acid methyl ester; (E)-2-[2-(2-amino-4-trifluoromethyl-phenylsulfanylmethyl)- phenyl]-3-methoxy-acrylic acid methyl ester; (E)-2-[2-(2-amino-4-methoxy-phenoxymethyl)-phenyl]-3-methoxy- acrylic acid methyl ester; (E)-2-[2-(4-tert-butyl-2-chloro-phenoxymethyl)-phenyl]-3-methoxy- acrylic acid methyl ester. IA3 Preferred compounds are also those of formula IA3 wherein R 1 is methyl, X is CH-, R 3 is H 2 , W is S, O, A 3 is phenyl, which may be substituted by one or more substituents, selected from hal, CF3, lower alkyl or is 5-acetoxy-6-acetoxymethyl-5,6-dihydro-2H-pyran. Such compounds can be prepared according to the procedure set out in example 118, like the following additional compounds: (E)-2-[2-[(E)-3-(5-Acetoxy-6-acetoxymethyl-5,6-dihydro-2H-pyran- 2-yloxy)-propenyl]-phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(E)-3-(2-chloro-phenylsulfanyl)-propenyl]-phenyl]-3- methoxy-acrylic acid methyl ester, (E)-2-[2-[(E)-3-(2-chloro-4-methyl-phenoxy)-propenyl]-phenyl]-3- methoxy-acrylic acid methyl ester, and (E)-2-[2-[(E)-3-(2-chloro-4-trifluoromethyl-phenoxy)-propenyl]- phenyl]-3-methoxy-acrylic acid methyl ester. IA4 Preferred compounds are also those of formula IA4 wherein R 1 is methyl, X is CH, and A 4 is phenyl, which may be substituted by one or more substituents, selected from hal, lower alkoxy, NO2, styryl-phenyl, or (2-CF3-, or Cl-phenyl)-furan-2-yl. Such compounds can be prepared according to the procedure set in example 126 (EP-475158 A2 920318), like: (E)-3-Methoxy-2-[2-[(E)-2-[5-(2-trifluoromethyl-phenyl)-furan-2-yl]- vinyl]-phenyl]-acrylic acid methyl ester, (E)-2-[2-[(E)-2-(2-chloro-3,4-dimethoxy-6-nitro-phenyl)-vinyl]- phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(E)-2-[5-(2-chloro-phenyl)-furan-2-yl]-vinyl]-phenyl]-3- methoxy-acrylic acid methyl ester and (E)-3-methoxy-2-[2-[(E)-2-[(E)-4-styryl-phenyl]-vinyl]-phenyl]- acrylic acid methyl ester. IA5 Preferred compounds are also those of formula IA5 wherein R 1 is methyl, X is CH, R 4 is H and A 5 is phenyl, which may be substituted by one or more substituents, selected from lower alkyl, lower alkoxy, NO 2 , hal, cyano, or CF3. Such compounds can be prepared according to the procedure set out in example 164, like: (E)-2-[2-[(lE,3E)-4-(2-Chloro-3,4-dimethoxy-phenyl)-buta-l,3- dienyl]-phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(2-bromo-4,5-dimethoxy-phenyl)-buta-l,3- dienyl]-phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(2-cyano-phenyl)-buta-l,3-dienyl]-phenyl]-3- methoxy-acrylic acid methyl ester, (E)-3-methoxy-2-[2-[(lE,3E)-4-(3-methoxy-2-nitro-phenyl)-buta-l,3- dienyl]-phenyl]-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(4-fluoro-2-trifluoromethyl-phenyl)-buta-l,3- dienyl]-phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(4-tert-butyl-phenyl)-buta-l,3-dienyl]-phenyl]- 3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(2-chloro-4-fluoro-phenyl)-buta-l,3-dienyl]- phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(2,4-difluoro-phenyl)-buta-l,3-dienyl]-phenyl]-3- methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(2-chloro-4-methyl-phenyl)-buta-l,3-dienyl]- phenyl]-3-methoxy-acrylic acid methyl ester, (E)-2-[2-[(lE,3E)-4-(2,4-dimethyl-phenyl)-buta-l,3-dienyl]-phenyl]- 3-methoxy-acrylic acid methyl ester and (E)-2-[2-[(lE,3E)-4-(2-fluoro-4-trifluoromethyl-phenyl)-buta-l,3- dienyl]-phenyl]-3-methoxy-acrylic acid methyl ester. IA6 IA9 IB3 IB5 The activity of the compounds against not only chloroquine- resistant, but also chloroquine-sensitive malaria pathogens shows itself in a strong, in vitro measurable growth inhibition of various strains of the human-pathogenic Plasmodium falciparum, as set forth in Table 1 hereinafter. The ratio of the growth inhibition of a strain which is especially resistant to chloroquine and of a strain which is sensitive to chloroquine gives as the "resistance index" a measurement for the absence or presence of a cross-resistance with chloroquine. Since, for all novel compounds the resistance index lies between 0.7 and 2.5, they inhibit the growth of sensitive as well as resistant strains of the malaria pathogen equally effectively. They are accordingly also suitable for the prophylaxis of a malaria disease and also for the treatment of a malaria disease even when chloroquine is ineffective. The good activity against malaria pathogens is also shown in animal experiments. The effective doses measured after oral and subcutaneous administration to mice infected with malaria pathogens are shown in Table 2 hereinafter. Test method for the determination of the activity against Plasmodium falciparum in vitro The preparations are tested on intraerythrocytary stages of Plasmodium falciparum from asynchronous cultures according to the method of Desjardin et al. (Desjardins, R.E. et al: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16, 710-718, (1979)). The culture medium consists of RPMI 1640 with the addition of 25 M HEPES, 25 mM NaHCOg, 100 μg/ml neomycin and 10% human serum (A + ). Human- A + erythrocytes are used as the Plasmodium falciparum host cells. The parasites are maintained at 37°C in an atmosphere of 3% O 2 , 4% CO 2 , 93% N 2 and 95% relative humidity. In order to determine the activity, the preparations are dissolved in DMSO, pre-diluted in the culture medium to a suitable starting concentration and subsequently titrated-out on to microtitre plates in the 2nd stage over 6-7 steps. After the addition of the parasite culture (0.7% parasitemia in 2.5% erythrocyte suspension) the test plates are incubated under the conditions given above for 72 h. The parasite growth in the different preparation concentrations is determined using [G- 3 H]-hypoxanthin incorporation compared to untreated control cultures on the same test plates. The 50% growth inhibition (IC50) is calculated according to logit regression analysis from the resulting dosage-activity curve. The preparations are tested on at least one chloroquine-resistant and one chloroquine-sensitive Plasmodium falciparum strain. Additional sensitive and resistant strains are included for futher characterization. Test method for the determination of the activity against Plasmodium berghei in vivo The preparations are tested on mice infected with malaria pathogens (Plasmodium berghei). Male albino mice (IBM:MORO(SPF), FUELLINSDORF) weighing about 25 g are used as the test animals. They are kept in climatized rooms at 21-22°C in groups of 5 animals per cage. They receive ad libitum a diet feed with a low P.ABA content (NAFAG FUTTER " No. 9009 PAB-45, PABA content 45 mg/kg) and drinking water. On the first day of the test (DO) the test animals are infected with Plasmodium berghei (strain ANKA). For this there is used heparinized blood of a donor mouse with about 30% parasitemia, which is diluted with physiological saline such that it contains 10 8 parasitized erythrocytes per ml. 0.2 ml of this suspension is injected intravenously (i.v.) into the mice to be treated and into the control mice. In untreated control animals the parasitemia normally reaches 30-40% on the third day after the infection (D+3) and the test animals die between days +5 and +7. The substances to be tested are dissolved or suspended in distilled water or in a mixture of 7% Tween 80, 3% alcohol (96%) and water. Usually, 0.25 ml of this solution or suspension is administered once subcutaneously and perorally to groups of 5 test animals. Treatment is effected 24 hours after the infection. 10 control animals are treated in the same manner with solvent or suspension medium per test. J II substances are tested in a first test in a single dosage of 100 or 10 mg/kg. Only those substances which in this test (10 mg/kg) have shown a parasitaemia reduction of more than 90% are used for the titration. Suitable dilutions of the test substance can be used to obtain an accurate titration of the activity. 48 hours after the treatment (D+3) blood smears are prepared from all animals using blood from tail veins and are stained with giemsa. The average erythrocyte infection rate (parasitemiea in %) in the control groups as well as in the groups which have been treated with the test compounds is determined by counting under a microscope. The difference in the average values of the infection rates of control group (100%) and treated groups is calculated and expressed as a percentage reduction (GI%). The ED 50 or ED90 is determined mathematically by means of the JMP programme (nonlinear fit). The ED 5 0 (ED 90 ) in mg/kg is that dose which after single administration reduces the average erythrocyte infection rate by 50% (90%) in comparison to the control group. Table 1 Values measured in vitro (IC50 values in μg/ml) for the grouth inhibition of the human-pathogenic Plasmodium falciparum strain NF54 as an example of a chloroquine-sensitive strain and of the human-pathogenic Plasmodium flaciparum Kl as an example of a chloroquine-resistant strain. Formula Example No. in vitro strain NF 54 strain Kl IC50 72 h IC50 72 h IA1 11 1.17 4.9 IA1 28 17.7 19.1 IA2 105 0.21 1.01 IA2 110 20 65.8 Table 2 Activity measured in vivo against Plasmodium berghei in mice in percentage reduction of the parasitemia after a perorally (po) or subcutaneously (sc) administered dose of 100 (10) mg/kg of test substance, ED 50 is the effective administered dose of test substance The compounds of formula LA or IB and the pharmaceutically acceptable acid addition salts of the compounds of formula LA or IB can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions, or nasally. The compounds of formula IA or IB and the pharmaceutically acceptable acid addition salts of the compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like. The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances. Medicaments containing a compound of formula IA or IB or a pharmaceutically acceptable acid addition salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their manufacture which comprises bringing one or more compounds of formula IA or IB and/or pharmaceutically acceptable acid addition salts thereof into a galenical administration form together with one or more therapeutically inert carriers. In accordance with the invention compounds of general formula IA or IB as well as their pharmaceutically acceptable acid addition salts can be used for the treatment or prevention of malaria and, respectively, for the production of corresponding medicaments. The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In the case of oral administration the dosage lies in a range of about 10 mg to about 2.5 g per day of a compound of general formula IA or IB or the corresponding amount of a pharmaceutically acceptable acid addition salt thereof, although the upper limit can also be exceeded when this is found to be indicated. In the following Examples, which illustrate the present invention but are not intended to limit its scope in any manner, all temperatures are given in degrees Celsius. The 250 MHz- 1 H-NMR spectra were measured at room temperature; chemical shifts δ(ppm) relative to δ(TMS) = 0.0 ppm. The novel compounds of formula IA5 can be prepared as described below. All temperature are given in °C. Example 164 (E)-2-r2-(lE.3E)-4-[4.5-Dimethoxy-2-nitro-phenyl)-buta-1.3-dienyll- phenyll-3-methoxy-acrylic acid methyl ester a) At room temperature, NaOCHg (335 mg, 6.19 mmol) was added to a solution of l,3-dioxan-2-ylmethyltributylphosphoniumbromide (C. Spangler; R. McCoy, Synthetic communications, 18, 51, (1988)) (5.17 ml, 1M in DMF, 5.71 mmol) and 4,5-dimethoxy-2-nitro-benzaldehyde (1.25 g, 4.76 mmol) in DMF (20 ml). After heating the mixture at 50° for overnight, the mixture was poured over water, and extracted with ether, washed with brine and dried over MgSO 4 . The solvent was evaporated and the residue was dissolved in THF (100 ml) and treated with 2N HC1 (50 ml). After stirring the mixture at room temperature for 2 h, the THF was evaporated, and the yellow solid was filtered, and suspended in ether/ethylacetate 4:1. The suspension stirred at room temperature for 1 h, filtered and washed with ether to afford (E)-3-(4,5- dimethoxy-2-nitro-phenyl)-propenal (624 mg, 55%) as a yellow solid, m.p. 103-105°. IR (KBr): 1689, 1605 cm' 1 . MS (El): 237 (M). b) At 0°, NaH (40 mg, 0.954 mmol) was added to a solution of (E)-2- [2-(dimethoxy-phosphorylmethyl)-phenyl] -3-methoxy-acrylic acid methyl ester (EP-203606) (250 mg, 0.79 mmol) in THF (5 ml). The mixture was stirred at room temperature for 30 min and treated with (E)-3-(4,5-dimethoxy-2-nitro-ρhenyl)-propenal (189 mg, 0.79 mmol) in CH 2 C1 2 (2 ml). After the mixture was stirred at room temperature for 3 h and refluxed for 1.5 h, the reaction mixture was cooled to room temperature and treated with CHgCO 2 H (1 ml). After stirring for 10 min at room temperature, the reaction mixture was extracted with ethylacetate, washed with NaHCOg solution, brine, water, and dried over M SO . Evaporation of the solvent and chromatography (hexane/ethylacetate 1:1) gave (E)-2-[2-(lE,3E)-4-[4,5-dimethoxy-2- nitro-phenyl)-buta-l,3-dienyl] -phenyl] -3-methoxy-acrylic acid methyl ester (116 mg, 34%) as white solid, m.p. 198-200°. IR (KBr): 1710, 1630 cm- l . MS (El): 425 (M). According to the procedure set forth in the preceding example, the following compounds were prepared: Example 165 (E)-2-r2-r(lE.3E)-4-(2.4-Dichloro-phenyl)-buta-1.3-dienvn-phenvn-3- methoxy-acrylic acid methyl ester m.p. 143-145° IR (KBr): 1707, 1629 cmX MS (El): 388 (M). Example 166 Methyl (E and/or Z)-3-methoxy-2-ro-ι r (all-E)-4-(2-pyridyl)-1.3- butadienyll phenyll acrylate m.p. 106-108° Example 167 Methyl (E and/or Z)-2-ι r o-r(all-E)-4-(2.3-dichlorophenyl)-1.3-butadienyll- phenyl] -3-methoxyacrylate m.p. 141-145° Example 168 Methyl (E and/or Z)-2-ro-r(all-E)-4-(2.3-difluorophenyl)-1.3-butadienyll- phenyll -3-methoxyacrylate m.p. 142-144° Example 169 Methyl (E and/or Z)-3-methoxy-2-ro-r(all-E)-4-(2-quinolinyl)-1.3- butadienyll phenyll acrylate m.p. 137-138° Example 170 Methyl (E and/or Z)-3-methoxy-2-ro-f(all-E)-4-(l-naphthyl)-1.3- butadienyll phenyll acrylate m.p. 138-140° Example 171 Methyl (E and or Z)-3-methoxy-2-ro-Kall-E)-4-(l-methylpyrrol-2-yl)-1.3- butadienyll phenyll acrylate m.p. 139-142° Example 172 Methyl (E and/or Z)-3-methoxy-2-ro-r(all-E)-4-(4-pyridyl)-1.3- butadienyll phenyll acrylate m.p. 175-177° Example 173 Methyl (E and/or Z)-2-ro-r(all-E)-4-(2-furyl)-1.3-butadienyl]phenyll-3- methoxyacrylate m.p. 136-137° Example 174 Methyl (E and/or Z)-3-methoxy-2-ro-r(all-E)-4-(2-thienyl)-1.3- butadienyl] phenyll acrylate m.p. 142-145° Example 175 Methyl (E and or Z)-3-methoxy-2-ro-r(all-E and or Z)-4-(3-thienyl)-1.3- butadienvH phenyll acrylate m.p. 194-195° Example 176 Methyl (E and or Z)-3-methoxy-2-[o-f(all-E)-4-(3-quinolinyl)-1.3- butadienyll phenyll -3-methoxyaerylate m.p. 173-175° Example 177 Methyl (E)-3-methoxy-2-[o- r ι(all-E)-4-(alpha.alpha.alpha-trifluoro-p- tolyl)-1.3-butadienynphenyl1acrylate m.p. 190-191° Example 178 Methyl (E)-2-ro-r(all-E)-4-(p-fluorophenyl)-1.3-butadienyl1phenvn-3- methoxyacrylate m.p. 156-157° Example 179 Methyl (E)-2-ro-[(all-E)-4-(o-ethoxyphenyl)-1.3-butadienyllphenyll-3- methoxyacrylate m.p. 152-153° Example 180 Methyl (E)-2-ro-f(all-E)-4-(2-chloro-6-fluorophenyl)-1.3- butadienyl] phenyll acrylate m.p. 165° Example 181 Methyl (E)-3-methoxy-2-fo-[(all-E)-4-(alpha,alpha.alpha-trifluoro-m- tolyl)-1.3-butadienvnphenyllacrylate m.p. 152-153° Example 182 Methyl (E)-2-ro-r(all-E)-4-(3-furyl)-1.3-butadienyllphenyll-3- methoxyacrylate m.p. 174-175° Example 183 Methyl (E)-2-ro- (all-E)-4-r2-(p-chloro-phenyl)-4-thiazolyll-1.3- butadienyll phenyll -3-methoxyacrylate m.p. 167-171° Example 184 Methyl (E)-2-ro-f(all-E)-4-(o-chlorophenyl)-1.3- butadienyll phenyll acrylate m.p. 158-162° Example 185 Methyl (E)-3-methoxy-2-ro-[(all-E)-4-(alpha.alpha.alpha-trifluoro-tolyl)- 1 , 3 -butadienyll phenyll acrylate m.p. 148-149° Example 186 Methyl (E)-2-ro-r(all-E)-4-(m-fluorophenyl)-1.3-butadienvnphenvn-3- methoxyacrylate IR (KBr): 1705, 1628 cm- 1 , MS (El): 338 (M) Example 187 Methyl (E)-3-methoxy-2-ro-r(all-E)-4-(5-phenyl-4-thiazolyl)-1.3- butadienyll phenyll acrylate m.p. 167° Example 188 Methyl (E)-2-ro- all-E)-4-(5-bromo-2-thienyl)-1.3-butadienvnphenyll-3- methoxyacrylate m.p. 160-161° Example 189 Methyl (E)-3-methoxy-2-ro- (all-E)-4-(p-methoχyphenv -1.3-butadienyl1- phenyll acrylate m.p. 164-166° Example 190 Methyl (E)-3-methoxy-2- ro-r(all-E)-4- 3-methoxybenzo [bl thiophen-2-yll - 1.3 -butadienyll phenyll acrylate m.p. 202-203° Example 191 Methyl (E)-3-methoxy-2-fo-Kall-E)-3-(2-thiazolyl)-1.3- butadienyll phenyll acrylate m.p. 131-133° Example 192 Methyl (E)-3-methoxy-2-ro-Kall-E)-4-(5-methyl-2-thienyl)-1.3- butadienyll phenyll acrylate m.p. 131-133° Example 193 Methyl (E)-3-methoxy-2-ro-r(all-E)-4-(3-methyl-2-thienyl)-1.3- butadienyl] phenyl] acrylate m.p. 168° Example 194 Methyl (E)-3-methoxy-2-ro-f4-(2-naphthyl)-1.3- butadienyll phenyll acrylate m.p. 172° Example 195 Methyl (E)-2-ro-r(all-E)-4-benzo b]thiophen-2-yl-1.3-butadienyllphenyll- 3-methoxy-acrylate m.p. 223-225° Example 196 Methyl (E)-2-ro-Kall-E)-4-benzofolthiophen-3-yl-l,3-butadienyllphenyl]- 3-methoxy-acrylate m.p. 157° Example 197 Methyl (E)-3-methoxy-2-,o-[(all-E)-4-phenyl-1.3- butadienyll phenyl] acrylate m.p. 165-167° Example 198 (E)- or (Z)-2-f2-r4-(3.5-bis-trifluoromethyl-phenyl)-buta-1.3- dienyll phenyll -3-methoxy- acrylic acid methyl ester IR (KBr): 1703, 1630 cm- 1 MS (El): 456 (M) Example 199 (E)- or (Z)-2-f2-r4-(2.4-bis-trifluoromethyl-phenyl)-buta-1.3- dienyll phenyll -3-methoxy-acrylic acid methyl ester m.p. 176-177° IR (KBr): 1703, 1630 cm- 1 MS (El): 456 (M) Example 200 Methyl-2- o-r(all-E)-4-(m-bromophenyl)-1.3-butadienvnphenyll-3- methoxyacrylic IR (KBr): 1701, 1626 cm-1 MS (El): 399 (M) Example 201 Methyl (E)-2-ro- r ι(all-E)-4-(p-chlorophenyl)-1.3-butadienyllphenvn-3- methoxyacrylate m.p. 209° Example 202 Methyl (E)-2-ι r o-r(all-E)-4-(m-chlorophenyl)-1.3-butadienyllphenyll-3- methoxyacrylate m.p. 121-122° Example 203 Methyl (E)-2-ro- r(all-E)-4-(o-bromophenyl)-1.3-butadienyll phenyll -3- methoxyacrylate m.p. 150-151° Example 204 Methyl (E)-3-methoxy-2-fo-r(all-E)-4-(3.4.5-trimethoxyphenyl)-1.3- butadienyll phenyll acrylate m.p. 98-102° Example 205 Methyl (E)-2-ro- (all-E -4-(p-tert-butylphenyl)-3-methyl-1.3-butadienvn- phenyll3-methoxyacrylate IR (KBr): 1709, 1632 cπX MS (El): 390 (M) Example 206 (Z)- or (E)-Methoxyimino-ι r 2-r(lE.2E)-4-(2-trifluoromethylphenyl)-buta- 1.3-dienyll-phenyll-acetic acid methyl ester a) At 24°, BugSnH (0.56 ml, 2.1 mmol) was added to a solution of (2-ethynyl-phenyl)-methoxyimino-acetic acid methyl ester (151 mg, 0.7 mmol) and AIBN (cat.) in toluene (0.5 ml). After the mixture was stirred at 80° for 3.5 h, solvent was evaporated under reduced pressure and chromatography (hexane/ethylacetate 9:1) gave methoxyimino-[2-(E,Z)- (2-tributylstannanyl-vinyl)-phenyl]-acetic acid methyl ester (1:1 mixture) (155 mg, 44%) as a yellowish liquid. IR (KBr): 1731, 1600 cm *1 . MS (El): 508 (M). b) A solution of l-(2,2-dibromo-vinyl)-2-trifluoromethyl-benzene (989 mg, 3 mmol), and (Et) 2 POH (0.75 ml, 6 mmol) in EtgN (0.83 ml, 6 mmol) was stirred at 5° for 4 h. Hexane was added, and stirred for further 10 min. The mixture was extracted with hexane, washed with brine and dried over Na2SO . Evaporation of the solvent and chromatography (hexane) gave l-(2-bromo-vinyl)-2-trifluoromethyl- benzene (674 mg, 90%) as a colorless liquid. IR (KBr): 1600, 940 cm "1 . MS (El): 251 (M). c) At 24°, Pd[PPhg (21 mg, 0.02 mmol) was added to a solution of 1- (l-bromo-vinyl)-2-trifluoromethyl-benzene (151 mg, 0.6 mmol) and methoxyimino-[2-(E,Z)-(2-tributylstannanyl-vinyl)-phenyl]-acetic acid methyl ester (304 mg, 0.6 mmol) in toluene (5 ml). The mixture was stirred at 110° for 5 h, cooled to room temperature, extracted with toluene, washed with brine, and dried over Na2SO4. Evaporation of the solvent and chromatography (hexane/ ethylacetate 3:2) gave (Z)- or (E)- methoxyimino-[2-[(lE,2E)-4-(2-trifluoromethylphenyl)-buta-l,3-dienyl]- phenyl] -acetic acid methyl ester (48 mg, 21%) as brown oil. IR (KBr): 1734, 1610 cm-1. MS (El): 389 (M). Example 251 (III) (E)-3-Methoxy-2-f(E)-2- R)- and (S)-3-(tetrahvdro-pyran-2-yloχy}- propenyll-phenyll-acrylic acid methyl ester (active intermediate) At 24°, Pd[PPhg] (58 mg, 0.05 mmol) was added to a solution of (E)-tributyl-[3-(R)- and (S)-(tetrahydro-pyran-2-yloxy)-propenyl]- stannane (2.2 g, 5.1 mmol) (E.J. Corey; J.W. Suggs, J. Org. Chem. 40, 2554, (1975)) and (E)-2-(2-bromo-phenyl)-3-methoxy-acrylic acid methyl ester (1.38 mg, 5.1 mmol) (EP 0307101 A2 890315) in toluene (20 ml). The mixture was stirred at 110° for 2 days, cooled to room temperature, extracted with toluene, washed with brine, and dried over Na2SO4. Evaporation of the solvent and chromatography (hexane/ethylacetate 9:1) gave (E)-3-methoxy-2-[(E)-2-[(R)- and (S)-3-(tetrahydro-pyran-2- yloxy)-propenyl] -phenyl] -acrylic acid methyl ester (884 mg, 52%) as a white solid, m.p. 66-68°. IR (KBr): 1711, 1633 cm-1. S (El): 216 (M- MeOH-Dihydropyrane). Example 252 (IV) (E)-2-f2-(3-Hvdroxy-propenyl)-phenyll-3-methoxy- acrylic acid methyl ester (active intermediate) At 24°, toluene-4-sulfonic acid monohydrate (1.11 g, 0.4 mmol) was added to a solution of (E)-3-methoxy-2-[(E)-2-[(R)- and (S)-3-(tetrahydro- pyran-2-yloxy)-propenyl] -phenyl] -acrylic acid methyl ester (4.866 g, 14 mmol) in ethanol (70 ml). After the mixture was stirred for 6 h and neutralized with K2CO3 solution, the solvent was evaporated and the crude was dissolved in ethylacetate, washed with brine, water, and dried over Na2SO4. Evaporation of the solvent gave (E)-2-[2-(3-hydroxy- propenyl)-phenyl]-3-methoxy-acrylic acid methyl ester (3.4 g, 93%) as a white solid, m.p. 78-80°. IR (KBr): 1683, 1619 cm-1. MS (El): 216 (M- MeOH). Example A (E)-2-[2-(lE,3E)-4-[4,5-Dimethoxy-2-nitro-phenyl)-buta-l,3-dienyl]- phenyl] -3 -methoxy acrylic acid methyl ester can be formulated as the active ingredient according to methods known per se to give pharmaceutical preparations of the following composition: 1. 500 mg tablets Active ingredient 500 mg Powd. lactose 149 mg Polyvinylpyrrolidone 15 mg Dioctyl sodium sulphosuccinate 1 mg Na carboxymethylstarch 30 mg Magnesium stearate 5 mg 700 mg 2. 50 mg tablets Active ingredient 50 mg Powd. lactose 50 mg Microcrystalline cellulose 82 mg Na carboxymethylstarch 15 mg 200 mg 3. 100 mg capsules Active ingredient 100.0 mg Powd. lactose 104.7 mg Corn starch • 70.0 mg Hydroxypropylmethylcellulose 10.0 mg Dioctyl sodium sulphosuccinate 0.3 mg Talc 12.0 mg Magnesium stearate 3.0 mg 300.0 mg 4. 500 mg suppositories Active ingredient 500 mg Suppository mass ad 2000 mg 5. 100 mg soft gelatine capsules Active ingredient 100 mg Medium chain triglyceride 300 mg 400 mg

Claims: Claims 1. The use of compounds of formulae IA or IB wherein Rl is lower alkyl X is N or CH A 1 R in IA is W^ Ial wherein Y is S or O and A l is phenyl, which may be substituted by one or more substituents, selected from halogen, lower alkoxy, lower alkyl, CFg, NO 2 , NH2, phenoxy or CF3- phenoxy; naphthyl; isothiazol-3-yl; thiazol-2-yl, optionally substituted by lower alkoxy alkoxy alkyl, lower alkyl, lower alkoxycarbonyl or lower acetoxyalkyl; thiadiazol-2-yl, optionally substituted by lower alkylthio, lower alkinylthio, cycloalkyl- alkylthio, CFg or -NHC 6 H 4 CFg; quinoxalin-2-yl, optionally substituted by halogen or lower alkyl; benzoxazol-2-yl; benzotriazine, optionally substituted by an oxo-group; and quinolin-2-yl; wherein R 2 is hydrogen, lower alkoxycarbonyl, CFg, lower alkyl, cycloalkyl, lower alkoxyalkyl, lower alkylthio alkyl or lower alkoxy and A 2 is phenyl, which may be substituted by one or more substituents, selected from lower alkyl, CFg, halogen, lower alkylthio, lower alkoxy or NO 2; -C(O)C 6 H 5 ; -C(CH 3 )=CH-C 6 H 4 -lower alkyl; -CH=CH-C6H5; pyridin-2-yl; pyridin-3-yl; pyridin- 4-yl; thiazol-5-yl, optionally substituted by lower alkyl; thien-3-yl, optionally substituted by lower alkyl; thien-2-yl, optionally substituted by halogen; quinolin-2-yl; naphthyl, benzo[b]thiophen-2-yl, optionally substituted by lower alkyl or halogen; or benzo[b]furan-2-yl; R 3 A or ^ " ' W Ia3 wherein W is S, O, NH or CH 2 ; R 3 is hydrogen or lower alkyl and A 3 is 5-acetoxy-6-acetoxvmethyl-5,6-dihydro-2H- pyran or phenyl, which may be substituted by one or more substituents, selected from halogen, CFg or lower alkyl; or ^^ Ia4 wherein A 4 is phenyl, which may be substituted by one or more substituents, selected from NO2, lower alkoxy, halogen, CFg, phenyloxy, styryl-phenyl or (2-CF3- or Cl-phenyl)-furan-2-yl; benzo[l,3]dioxol- 5-yl, optionally substituted by halogen; isoxazol-4- yl, optionally substituted by phenyl or lower alkoxyalkoxy; quinolin-3-yl; pyridin-2-yl; pyridin- 3-yl, pyridin-4-yl; furyl; thien-2-yl; thien-3-yl; - C=C-C(CHg) 3 ; -C≡C-C 6 H 5 ; indolizin-2-yl, optionally substituted by lower alkyl; benzofuran- 2-yl; benzopyran-3-yl or dihydrobenzo[b]thiophen- 5-yl; wherein R 4 is hydrogen or lower alkyl; and A 5 is phenyl, which may be substituted by one or more substituents, selected from lower alkyl, lower alkoxy, NO2, halogen, cyano or CFg; pyridin-2-yl; pyridin-4-yl; quinolin-2-yl; quinolin-3-yl; naphthyl; pyrrol-2-yl, optionally substituted by lower alkyl; furan-2-yl, furan-3-yl; thien-2-yl; thien-3-yl, optionally substituted by halogen and lower alkyl; thiazol-2-yl, optionally substituted by C6H4CI; thiazol-4-yl, optionally substituted by phenyl; benzo[b]thiophen-2-yl, optionally substituted by halogen; or benzo[b]thiophen-3-yl; wherein A 6 is phenyl, optionally substituted by CFg; -* " A Ia7 wherein A 7 is phenyl, optionally substituted by CFg; or -(CH2)n-A 8 Ia8 wherein n is 4 and A 8 is phenyl, which may be substituted by one or more substituents, selected from CFg, halogen or -CH=N-OCH 2 -CO-OCH 3 ; naphthyl or pyridin-4-yl; wherein A 9 is phenyl, optionally substituted by CFg; and wherein in formula IB R 6 -R 8 are hydrogen, lower alkyl or lower alkoxy and Z is hydrogen; lower alkoxy; lower alkyl; or halogen or v Ibi wherein V is O, -N(CHg)-, -S- and B 1 is phenyl, optionally substituted by halogen or alkyl; quinolin-8-yl; pyrimidin-2-yl; -CH(CHg)- C 6 H 5 ; or -CH 2 -C 6 H 5 ; wherein m is 0 or 1; and B 2 is phenyl, optionally substituted by halogen, lower alkyl or CFg; or benzo[b]thiophen-5-yl; O or ' ° ' ^ ' B 3 ib3 wherein B 3 is phenyl, optionally substituted by CFg; wherein R 5 is hydrogen, lower alkyl or lower alkoxy alkyl and B 4 is phenyl, optionally substituted by CFg; pyridin- 2-yl; or thiazolin-5-yl, optionally substituted by lower alkyl; or ^^ Ib5 wherein B 5 is phenyl; -C≡C-C(CHg)g; or thien-3-yl; as well as pharmaceutically acceptable salts and possible stereoisomers as well as their racemates of compounds of formulae IA and IB as therapeutically active substances. 2. The use according to claim 1 against chloroquine-sensitive and chloroquine-resistant pathogens and respectively, for the production of corresponding medicaments. 3. The use according to claims 1 to 2 of compounds of formula IA from the group of compounds wherein R 1 , X, Y and A 1 have the significances given in claim 1. 4. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds wherein R 1 , X, R 2 and A 2 have the significances given in claim 1. 5. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds IA3 wherein R l , X, R 3 , W and A 3 have the significances given in claim 1. 6. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds IA4 wherein R l , X and A 4 have the significances given in claim 1. 7. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds IA5 wherein R l , X, R 4 and R 5 have the significances given in claim 1. 8. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds IA6 wherein R l , X and A 6 have the significances given in claim 1. 9. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds wherein R l , X and A 7 have the significances given in claim 1. 10. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds wherein R l , X, n and A 8 have the significances given in claim 1. 11. The use according to claims 1 and 2 of compounds of formula IA from the group of compounds IA9 wherein R l . X and A 9 have the significances given in claim 1. 12. The use according to claims 1 and 2 of compounds of formula IB from the group wherein Rl, X, V and Bl have the significances given in claim 1. 13. The use according to claims 1 and 2 of compounds of formula IB from the group wherein Rl, X, m and Bl have the significances given in claim 1. 14. The use according to claims 1 and 2 of compounds of formula IB from the group IB3 wherein Rl, X and B 3 have the significances given in claim 1. 15. The use according to claims 1 and 2 of compounds of formula IB from the group wherein Rl, X, R 5 and B 4 have the significances given in claim 1. 16. The use according to claims 1 and 2 of compounds of formula IB from the group IB5 wherein Rl, X and B 5 have the significances given in claim 1. 17. The use according to claims 1 and 2 of compounds of formula IB, wherein R 6 , R 7 and R 8 have the significances given in claim 1 and Z is lower alkoxy, lower alkyl, halogen or hydrogen. 18. Compounds of formula wherein Rl is lower alkyl, X is N or CH, R 4 is hydrogen or lower alkyl and A 5 is phenyl, which may be substituted by one or more substituents, selected from lower alkyl, lower alkoxy, NO 2 , halogen, cyano or CFg; pyridin-2-yl; pyridin-4-yl; quinolin-2- yl; quinolin-3-yl; naphthyl; pyrrol-2-yl, optionally substituted by lower alkyl; furan-2-yl, furan-3-yl; thien-2-yl; thien-3-yl, optionally substituted by halogen and lower alkyl; thiazol-2-yl, optionally substituted by C 6 H 4 CI; thiazol-4-yl, optionally substituted by phenyl; benzo[b]thiophen-2-yl, optionally substituted by halogen; or benzo[b]thiophen-3-yl; as well as their pharmaceutically acceptable salts and possible stereoisomers as well as their racemates. 19. A medicament, especially for the treatment and/or prevention of malaria, containing one or more compounds according to any one of claims 1-16 and at least one therapeutically inert excipient. 20. The invention as hereinbefore described.

Inventors: ALZEER JAWAD, CHOLLET JACQUES, HUBSCHWERLEN CHRISTIAN, MATILE HUGUES, RIDLEY ROBERT GEORGE, ALZEER, JAWAD, CHOLLET, JACQUES, HUBSCHWERLEN, CHRISTIAN, MATILE, HUGUES, RIDLEY, ROBERT, GEORGE
Applicants: HOFFMANN LA ROCHE, F. HOFFMANN-LA ROCHE AG
Application year: 1998
Main classification: A61K31
IPC codes: A61K31, A61P33, C07C69, C07C229, C07C251, C07C323, C07D207, C07D213, C07D215, C07D217, C07D241, C07D277, C07D285, C07D307, C07D311, C07D317, C07D333, C07D409, C07D417, C07D471